E_DEPRECATED Error in file »functions_general.php« at line 301: Function utf8_encode() is deprecated Santhera - ProfileE_DEPRECATED Error in file »functions_general.php« at line 348: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 301: Function utf8_encode() is deprecated

PharmiNews

Directory of Pharma Companies and News

Company Profile

E_DEPRECATED Error in file »functions_general.php« at line 301: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 357: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 375: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 400: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 317: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 292: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 284: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 348: Function utf8_encode() is deprecated

Santhera

E_DEPRECATED Error in file »functions_general.php« at line 326: Function utf8_encode() is deprecated
E_DEPRECATED Error in file »functions_general.php« at line 326: Function utf8_encode() is deprecated Santhera logoE_DEPRECATED Error in file »functions_general.php« at line 186: Function utf8_encode() is deprecated
Category
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.
Keywords:
Finance Jobs News Website
E_DEPRECATED Error in file »company-code.php« at line 190: Function utf8_encode() is deprecated E_DEPRECATED Error in file »functions_general.php« at line 301: Function utf8_encode() is deprecated

Santhera News

DateNews
2019-08-27Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension Study Results with Vamorolone in Patients wi... (PDF)
2019-08-09Santhera Announces Executive Management Change (PDF)
2019-08-02Santhera Announces Closing of Licensing Transaction with Chiesi Group for Raxone® in LHON (PDF)
2019-06-25EMA Validates Santhera’s Marketing Authorization Application for Puldysa® in Duchenne Muscular Dystrophy (PDF)
2019-06-24UK’s MHRA renews EAMS Scientific Opinion for Santhera’s Idebenone in Duchenne Muscular Dystrophy (PDF)
2019-05-28Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting (PDF)
2019-05-27Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in Duche... (PDF)
2019-05-23Santhera Enters into License Agreement with Chiesi Group for Raxone® in LHON Valued at up to CHF 105 Million (PDF)
2019-05-21Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University... (PDF)
2019-04-29Santhera Reports Strong Top-line Growth for 2018 and the Successful Expansion of its Rare Disease Pipeline (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma